EBIT (Quarterly)

EBIT: Income before interest and taxes.

Ascendis Pharma A/S (ASND) had EBIT of $29.04M for the most recently reported fiscal quarter, ending 2026-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2026-03-31

Income Statement Financials
Revenue	$288.62M
Net Income	$736.58M
Cost of Goods Sold	$20.50M
Gross Profit	$268.12M
Operating Expenses	$259.58M
Operating Income	$29.04M
Non-Operating Income/Expense	$-85.43M
Pre-Tax Income	$-56.39M
Normalized Pre-Tax Income	$-56.39M
Income after Taxes	$736.58M
Income from Continuous Operations	$736.58M
Consolidated Net Income/Loss	$736.58M
Normalized Income after Taxes	$736.58M
EBIT	$29.04M
EBITDA	$33.98M
Weighted-Average Shares Outstanding (Basic)	61.68M
Weighted-Average Shares Outstanding (Diluted)	64.52M
Earnings per Share (EPS) (Basic)	$11.94
Earnings per Share (EPS) (Diluted)	$11.41
Balance Sheet Financials
Current Assets	$1.31B
Property, Plant, and Equipment	$159.08M
Long-Term Assets	$1.03B
Total Assets	$2.34B
Current Liabilities	$1.32B
Long-Term Debt	$451.90M
Long-Term Liabilities	$454.75M
Total Liabilities	$1.77B
Common Equity	$571.12M
Tangible Shareholders Equity	$566.81M
Shareholders Equity	$571.12M
Common Shares Outstanding	62.11M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-9.04M
Cash Flow from Investing Activities	$-7.90M
Cash Flow from Financial Activities	$-43.11M
Beginning Cash	$721.01M
End Cash	$670.43M
Increase/Decrease in Cash	$-50.59M
Stock-Based Compensation	$35.53M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.00
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.44
Debt to Equity Ratio	1.84
Gross Margin	92.90%
Operating Margin	10.06%
EBIT Margin	10.06%
EBITDA Margin	--
Pre-Tax Profit Margin	-19.54%
Profit Margin	255.21%
Free Cash Flow	$-18.06M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.12
Inventory Turnover	0.06
Receiveable Turnover	1.25
Days Sales in Receivables	71.75
Return on Equity	128.97%
Return on Tangible Equity	129.95%
Return on Assets	31.42%
Return on Investments	72.00%
Book Value Per Share	$9.20
Free Cash Flow per Share	$-0.28
Operating Cash Flow per Share	$-0.14

Data from Zacks Investment Research, Inc.